People with multiple sclerosis (MS) who start treatment with a mild-to-moderate efficacy disease-modifying therapy (DMT) were more likely to switch to another DMT, an analysis of the German MS Registry finds. Starting a DMT between 2014 and 2017 was also a predictor of switching. Disease activity despite treatment…

In 2010, I strolled into a new hospital to meet my new neurologist. In them there far-off days, I was indeed strolling — nay, striding — but it wouldn’t last. I was surrounded by an aura of self-confidence that anyone who’s survived the vicissitudes of nearly three decades of show…

Assessing disease activity from the first to second year after a diagnosis of multiple sclerosis (MS), once treatment has been initiated and stabilized, can help predict long-term disability outcomes. That’s according to the study, “Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term…

It’s time for another update on how I’ve been doing with my Lemtrada (alemtuzumab) treatments. The bottom line is that I’m doing well. Lemtrada is a disease-modifying therapy (DMT) delivered in two stages. The first stage entails a series of five daily infusions, while the second stage involves…

DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making What’s the best way to attack multiple sclerosis when it’s first diagnosed? Do you hit it hard and fast using the most effective disease-modifying therapy (DMT), or do you start with a lower efficacy DMT and slowly ramp up?…

FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a…

Initial treatment of relapsing-remitting multiple sclerosis (RRMS) with Gilenya (fingolimod), Tysabri (natalizumab), or Lemtrada (alemtuzumab) is associated with a lower risk of conversion to secondary progressive multiple sclerosis (SPMS), compared with interferon beta or Copaxone (glatiramer acetate), a study reports. Findings also showed that…